FOLH1 and posterior cortical atrophy: Given the rationale of adding angiogenesis inhibitors to ICI in order to break resistance towards immune-based approaches (73–75), it also appears tempting to assume that targeting PSMA could have an impact on the immunogenicity of PCa.